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Abstract Atrial fibrillation (AF) is part of a vicious
cycle that includes multiple cardiovascular risk fac-
tors and comorbidity which can promote atrial re-
modelling and AF progression. Most AF-related risk
factors—hypertension, diabetes, sleep apnoea, obe-
sity and sedentary lifestyle—are in essence modifiable
which may prevent AF development. Treatment of as-
sociated cardiovascular conditions may prevent both
symptoms and future cardiovascular events. For ad-
vanced forms of symptomatic AF refractory to lifestyle
management and optimal medication, invasive abla-
tion therapies have become a cornerstone. Although
electrical trigger isolation from the pulmonary veins
is reasonably effective and safe, more potent en-
ergy sources including high output-short duration
radiofrequency, ultra-low cryo-energy, and electropo-
ration, as well as more sophisticated arrays, balloons,
and lattice-tipped catheter tools, are on their way
to eliminate existing pitfalls and simplify the pro-
cedure. Electroanatomical navigation and mapping
systems are becoming available to provide real-time
information on ablation lesion quality and the critical
pathways of AF in the individual patient to guide more
extensive ablation strategies that may enhance long-
term outcome for freedom of advanced AF. Surgi-
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cal techniques, either stand-alone or concomitant to
structural cardiac repair, hybrid, or convergent, with
novel less invasive access options are developing and
can be helpful in situations unsuitable for catheter
ablation.
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Introduction
Atrial fibrillation (AF) is a progressive disease, associ-
ated with increasedmorbidity andmortality [1]. Many
factors contribute to the progression from infrequent
paroxysms suppressible by drug therapy to prolonged
symptomatic episodes that require chemical or elec-
trical cardioversion, to chronic rhythm abnormality
that may lead to exercise intolerance and heart failure.
It is this more chronic state of prolonged arrhythmias
that has been found most resistant to acute therapies
such as antiarrhythmic drugs and invasive interven-
tions. In this review we focus on the multifactorial
approach that may be useful and needed to improve
treatment outcomes.
Lifestyle and comorbidity
Multiple cardiovascular risk factors are associated
with the development and progression of AF. Atrial
remodelling caused by these risk factors can promote
AF and its recurrence. The majority of the AF-related
risk factors—hypertension, diabetes, sleep apnoea,
obesity, and sedentary lifestyle—are in essence mod-
ifiable and should be considered in the prevention
and treatment of AF [2]. Treatment of associated car-
diovascular conditions is of great importance since
this treatment can reduce AF burden and symp-
tomatology, but can also reduce the risk of future
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cardiovascular events [2]. This is in contrast to many
other AF therapies that only have an effect on either
AF burden or prognosis.
Hypertension is known to be the most common
risk factor for AF. It has been reported that the preva-
lence of hypertension in AF ranges from 49–90% [3].
Even borderline hypertension is associated with in-
creased risk for incident AF [4]. Optimal treatment of
hypertension with angiotensin-converting enzyme in-
hibitors and angiotensin II receptor blockers has been
shown to reduce the risk [5]. The RACE 3 trial showed
that with targeted treatment of underlying risk factors
of AF, such as reduction of blood pressure, mainte-
nance of sinus rhythm is more successful [6].
Various studies have shown a strong association
between obesity and AF [1]. A recent meta-analysis
showed that patients with obesity have a 1.5 times
higher risk than non-obese patients [7]. Furthermore,
the observational LEGACY trial showed that long-term
sustained weight loss reduced AF burden [8]. More-
over, moderate physical activity is also associated with
a reduction in AF [9]. This can partly be explained by
weight loss. However physical activity itself is also
a contributing factor for incident AF. Physical inactiv-
ity is associated with a higher risk of cardiovascular
events [10]. Improving physical activity may reduce
that risk, in incident AF by up to 10% [11]. It should be
noted that there is a U-shaped pattern between phys-
ical activity and risk of AF; extreme and prolonged ex-
ercise are considered to be a risk for AF [10, 12]. Offer-
ing patients the opportunity to participate in a cardiac
rehabilitation programme might stimulate patients to
be physically active and reduce the risk of AF recur-
rence [6].
Heart failure (HF) and AF often coexist sharingmul-
tiple risk factors. The epicardial adipose tissue may be
one of the underlyingmechanisms, as this local fat de-
pot is enlarged in patients with a combination of HF
and AF [13]. Furthermore, HF with preserved ejection
fraction and AF share the same signs and symptoms.
HF doubles the risk of incident AF. Treatment of HF
may prevent AF and reduce the risk of AF recurrence.
Treatment of HF with mineralocorticoid receptor an-
tagonists is associated with a reduction in incident AF
[14]. Moreover, it was associated with improvement
of sinus rhythm maintenance in the RACE 3 trial, as
well as in a meta-analysis of patients with AF in the
presence or absence of HF [6, 15].
Another known risk factor for AF is obstructive
sleep apnoea (OSA), which is often accompanied by
obesity [16]. The estimated prevalence of OSA in
AF patients is 50% [17]. Further, the risk of AF is
twofold higher for patients with OSA compared with
patients without OSA [18]. Treatment of OSA with
a continuous positive airway pressure device (CPAP)
has shown beneficial effects in recurrence of AF post-
ablation [19]. Therefore screening for OSA in AF pa-
tients should be considered [2]. Since AF is a complex
disease with multiple risk factors, comprehensive di-
agnosis and treatment of the underlying risk factors
should be implemented in the daily clinical care of
AF and should be part of the indication as well as the
periprocedural management in patients scheduled
for AF ablation.
Catheter ablation for AF
Since the seminal publication by Haissaguerre et al.[20]
in 1998, catheter ablation has become accepted ther-
apy for AF refractory to conventional treatment. Elec-
trical isolation of the pulmonary veins (PVI) was
found to prevent AF by effective elimination of trig-
gers, which remains the cornerstone for ablation
treatment [21]. The strategy evolved from focal appli-
cation of a radiofrequency current inside the veins, to
segmental linear ablation, to wide area circular abla-
tion, avoiding damage to the pulmonary veins while
aiming at eliminating as much ectopy generating tis-
sue as possible. Initially, freedom of AF was claimed
in more than 90% of patients, and technical devel-
opment led to electroanatomical navigation systems
to guide ablation. As these procedures required ex-
pensive equipment and remained long and difficult,
new catheter technologies were designed for quicker
‘single shot’ PVI. The phased radiofrequency multi-
electrode array and the cryoballoon came onto the
market[22, 23] and quickly became the most popular
single short ablation strategies, which were as effec-
tive as existing single-tip ablation catheter procedures
but with much shorter procedure times [24, 25]. The
major adverse event rate during AF ablation proce-
dures has become very low by increased operator
skills, mapping and navigation systems, and optimis-
ing periprocedural anticoagulation, such that stroke,
tamponade, severe groin bleeding and mortality have
become rare [25]. However, during clinical follow-up
and by using longer and more intense rhythm moni-
toring it has become apparent that recurrence of AF is
much more frequent than reported in the early days.
In the randomised FIRE&ICE trial comparing cryobal-
loon to irrigated radiofrequency single-tip ablation,
freedom of AF after 18 months was less than 70%. The
Dutch contribution to the field
 Drugs and lifestyle studies with global impact
from the Netherlands: RACE study programme
from the Universities of Groningen (Prof I. van
Gelder, Prof M. Rienstra) and Maastricht (Prof.
H. Crijns).
 Catheter ablation studies with global impact
from the Netherlands: Phased RF ablation stud-
ies (Prof L. Boersma).
 Surgical ablation studies with global impact from
the Netherlands: FAST trial (Prof L. Boersma);
AFACT trial (Prof J. De Groot).
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most common finding during redo-ablation remains
recurrence of electrical conduction between the left
atrium and one or more pulmonary veins, regardless
of how extensively the index ablation was performed
[26]. There is, however, still a potential for collat-
eral damage to the oesophagus, the phrenic nerve,
stroke due to char or thrombus embolisation, and
perforation of the wall. This has urged improvements
of existing technologies and strategies. Nowadays,
single-tip radiofrequency catheters are irrigated and
use contact-force sensing to perform safer, quicker,
and more effective wide area ablation around the
pulmonary vein, with improved AF freedom of up to
87% in low-risk patients with paroxysmal AF, if ap-
plications are done with optimal parameters and in
close proximity to each other [27]. Several companies
have developed new tools to create lesions with irri-
gated high-power output but short duration to retain
safety and efficacy while further shortening the abla-
tion time. New tools such as diamond-tip catheters
allow similar quick radiofrequency delivery with rapid
passive cooling by optimal heat exchange capacity,
while a novel lattice-tip mesh-based catheter may
allow more continuous lesion creation by conforming
better to the tissue surface [28]. The latest cryobal-
loon iterations by Medtronic and Boston Scientific
may provide more homogeneous circular freezing
with improved and quicker isolation and higher re-
ported freedom of AF outcomes. Still, the search for
easier, safer, and quicker procedures continues and
currently the field of AF ablation is exploding with
novel tools and energy forms such as multi-electrode
radiofrequency balloons and cryoballoon platforms
from Biosense-Webster and Boston Scientific, or Ada-
gio’s ultra-low temperature linear cryoablation with
custom-built stylet driven shape optimisation for var-
ious ablation targets. One of the most promising
new strategies is energy delivery by electroporation
which is being developed by various companies. By
delivering high voltage electrical field applications of
only nanoseconds in the proximity of the tissue, the
myocytes become irreversibly damaged without any
effect on local temperature and specific to myocardial
tissue, thereby avoiding char formation or insufficient
energy transmission and collateral damage to sur-
rounding structures. The next 5 years will reveal if all
these new technologies can live up to their promise
for improvement.
Aside from ablation technology, ablation strategy
also needs improvement in those with non-parox-
ysmal AF or comorbidities with structural left atrial
changes including dilatation and fibrosis, as PVI even
with extensive left atrial substrate ablation shows
freedom of AF in no more than half of the patients
[29]. As the ablation strategy may require a more
tailored individual approach, new strategies aim at
electroanatomical substrate visualisation. High-reso-
lution MRI may be used to determine left atrial wall
fibrosis, which may be incorporated in the ablation
strategy beyond PVI [30]. Several companies have de-
veloped systems for high-resolution mapping of elec-
trical activation during AF to determine the individual
AF mechanism to guide ablation. While TOPERA, the
first in its kind, could not live up to initial high expec-
tations (Brachmann et al. Heart Rhythm Society late-
breaking clinical trial 2019; unpublished data), other
technologies such as CardioInsight body surface map-
ping[31] and ACUTUS dipole density mapping[32] are
still developing and testing sophisticated technolo-
gies and algorithms to characterise individualised AF
patterns in real time to guide ablation and improve
outcomes for those where PVI alone is not enough.
New electroanatomical mapping technologies such
as KODEX (Philips)[33] or working in an MRI instead
of X-ray imaging environment (Philips/Imricor) may
further help guide and improve transmural lesion
creation by real-time tissue evaluation.
Advanced atrial fibrillation: treatment challenges
Whereas the preferred treatment strategy for patients
with uncomplicated, symptomatic, paroxysmal AF
has clearly become PVI via catheter ablation, the op-
timal strategy in patients with more advanced forms
of AF, evident from (long-standing) persistent AF,
a (severely) dilated left atrium or previously failed
catheter ablations, remains incompletely elucidated.
In general, those patients are older than patients
with paroxysmal AF and have more cardiovascular co-
morbidities, suggesting a more prominent place for
upstream treatment as outlined above [34]. If patients
with advanced AF are to be subjected to an invasive
procedure, which approach is indicated and which ad-
ditional ablation strategy should be added to the pul-
monary vein isolation to restore sinus rhythm in this
patient?
Before the emergence of catheter ablation, inva-
sive treatment of AF was confined to surgical treat-
ment. The Cox-Maze procedure, first described in
1987, underwent several modifications until the fi-
nal lesion sets in the Cox-Maze 3 and 4 were defined
[35]. Reported success rates were extremely high, but
the procedure was associated with considerable mor-
bidity and mortality, including an 8% pacemaker im-
plantation rate [36]. More recent studies on the long-
term follow-up, now including some form of rhythm
monitoring, show that at 5 years of follow-up 59% of
patients were in sinus rhythm (which is not equiva-
lent to absence of AF recurrence during 5 years) [37].
A recent randomised trial demonstrated AF freedom
in only 63% patients undergoing concomitant Maze
surgery duringmitral valve surgery, at the cost of more
pacemaker implantations [38]. Thus, attempts were
undertaken to combine the reported success rate of
the Maze operation with a less invasive approach [39].
This procedure was further refined into a totally thora-
coscopic procedure which, in a randomised compari-
son with standard of care catheter ablation in patients
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with mostly paroxysmal AF, yielded a higher efficacy
at the cost of more procedural complications (mainly
pneumothorax) [40, 41]. Recently, fewer complica-
tions have been reported [42]. A meta-analysis of all
randomised treatment arms of catheter or thoraco-
scopic AF ablation studies suggests a higher efficacy of
thoracoscopic ablation, but also again a slightly higher
rate of procedural complications [43].
Recurrences of atrial arrhythmias frequently con-
sist of atrial tachycardias, raising the question if trans-
mural lines can be created reliably using a thoraco-
scopic approach on a beating heart [44]. Several
approaches were developed to tackle this issue. Hy-
brid approaches complementing the thoracoscopic
procedure with a catheter-based endocardial or epi-
cardial mapping and ‘touch-up’ approach have been
described in a single procedure setting, as well as
in a staged setting [45–47]. Non-randomised data
suggest that this approach is more efficacious than
catheter ablation for persistent AF, and a randomised
study on this issue is ongoing [48].
The autonomic nervous system plays an important
role in the development of AF, and may be an at-
tractive ablation target [49]. Indeed, ablation of the
ganglion plexi added to PVI in patients with paroxys-
mal AF, was more efficacious than either of the two
strategies in isolation [50]. However, it could not be
excluded that the effect was due to more rigorous
ablation around the pulmonary veins. The AFACT
trial, randomising patients to a thoracoscopic abla-
tion with or without ablation of the ganglion plexus,
demonstrated that additional ganglion ablation with
radiofrequency energy does not improve the results
of the procedure but, to the contrary, is associated
with more procedural complications [51]. Indeed, as
mentioned above, the STAR-AF2 trial demonstrated
no added value of several additional ablation strate-
gies added to PVI in patients with persistent AF [29].
This leaves us with the question what the optimal
approach is towards patients with advanced AF. One
strategy to tackle this issue is to define an optimal
ablation approach in these patients. Therefore, the
multicentre APPROACH-AF study is now randomising
patients with persistent atrial fibrillation between PVI
only using state-of-the-art catheter ablation or tho-
racoscopic ablation and will provide data on the op-
timal ablation platform in those patients. A second
approach is to define the optimal patient for inva-
sive procedures. This requires understanding of the
molecular substrate of persistent AF, and the recogni-
tion that ablation in some patients may just be futile.
The PREDICT-AF study will provide insight into the
molecular fingerprint of patients developing AF, and
those who will remain free of AF [52].
We should acknowledge that there still is much we
do not know about AF, its mechanisms, clinical im-
plications, and optimal treatment. Although it may
appear as only an electrical disorder that causes an-
noying symptoms, it is often facilitated and enhanced
by many underlying pathophysiological mechanisms
and disease states related to morbidity and mortality
[1]. Although such underlying disease states may not
preclude positive effects of invasive AF treatment, so
far there is no hard evidence to support a reduction in
mortality [53, 54]. Achieving absolute freedom of AF
therefore remains a quest for the Holy Grail in decades
to come.
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